Sular and Hospitalisation - a phase IV clinical study of FDA data

Summary:

Hospitalisation is reported as a side effect among people who take Sular (nisoldipine), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Xyrem, and have Cataplexy.

The phase IV clinical study analyzes which people have Hospitalisation when taking Sular. It is created by eHealthMe based on reports of 1,710 people who have side effects when taking Sular from the FDA, and is updated regularly.

What is Sular?

Sular has active ingredients of nisoldipine. It is often used in high blood pressure. eHealthMe is studying from 1,757 Sular users. Check the latest studies of Sular.

What is Hospitalisation?

Hospitalisation is found to be associated with 1,716 drugs and 1,135 conditions by eHealthMe. Check the latest studies of Hospitalisation.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 28, 2026

1,710 people reported to have side effects when taking Sular.
Among them, 11 people (0.64%) have Hospitalisation.

Among these 11 people:

How long have people been on Sular when they have Hospitalisation? *

What is the gender of people who have Hospitalisation when taking Sular? *

female: 100 %
male: 0.0 %

What is the age of people who have Hospitalisation when taking Sular? *

What are other drugs people take besides Sular? *

What are other side effects people have besides Hospitalisation? *

Weight Decreased: 6 people, 54.55%
Diverticulitis (digestive disease which involves the formation of pouches (diverticula) within the bowel wall): 5 people, 45.45%
Attention Deficit Hyperactivity Disorder (a chronic condition including attention difficulty, hyperactivity, and impulsiveness): 5 people, 45.45%
Depression: 5 people, 45.45%
Drug Hypersensitivity: 5 people, 45.45%
Kidney Infection: 5 people, 45.45%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 4 people, 36.36%
Adrenal Cyst (cysts of the adrenal gland): 4 people, 36.36%
Type 2 Diabetes: 4 people, 36.36%
Fever: 4 people, 36.36%

What are the existing conditions these people have? *

Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 7 people, 63.64%
Cataplexy (loss of muscle tone accompanied by full conscious awareness): 7 people, 63.64%
Diabetes: 3 people, 27.27%
Cardiac Disorder: 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Sular and have Hospitalisation?

- Check whether Hospitalisation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Sular:

Sular (1,757 reports)

Hospitalisation treatments and more:

Hospitalisation (143,651 reports)

Browse all side effects of Sular:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hospitalisation:

Hospitalisation (1,716 drugs)

Browse all the conditions that are associated with Hospitalisation:

Hospitalisation (1,135 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on nisoldipine (the active ingredients of Sular) and Sular (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.